학술논문
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
Document Type
Article
Author
Source
In European Urology September 2022 82(3):283-292
Subject
Language
ISSN
0302-2838